Podcasts about cytokinetics

This episode of Don't Miss a Beat, recorded at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, explores the evolving landscape of heart failure with preserved ejection fraction (HFpEF) treatment, focusing on the implementation of combination therapies. Hosts Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss the transition from a previously limited treatment landscape to a new era with multiple proven therapeutic options. To open the episode, Greene argues in favor of rapid-sequence implementation of HFpEF therapies, drawing parallels to the established 4-pillar guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). He highlights 3 key classes of medications—SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and incretin-based therapies—as the foundation of HFpEF treatment. He emphasizes the importance of early and aggressive therapy initiation to maximize clinical benefits and reduce the risk of delayed or missed treatment opportunities among this population. Vaduganathan acknowledges the strength of the data supporting combination therapy but suggests a more risk-based approach, considering the broad clinical variability among HFpEF patients. He advocates for prioritizing rapid implementation in high-risk patients, such as those recently hospitalized, while allowing a more measured approach for lower-risk individuals. The discussion also touches on the role of phenotyping in tailoring treatment decisions, with GLP-1 receptor agonists being particularly relevant for patients with obesity and ARNi potentially benefiting those with mildly reduced ejection fraction. Looking ahead, the hosts preview upcoming trials, including CONFIDENCE and CONFIRMATION, which will evaluate combination therapy strategies in chronic kidney disease and HFpEF populations. They also discuss the potential of fixed-dose combination therapies to simplify implementation and improve adherence. The episode closes with both experts agreeing on the need for a structured, evidence-based approach to HFpEF treatment while emphasizing the importance of translating trial data into real-world practice. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00-Intro 02:30-Argument for Rapid Sequencing 05:32-Argument Against Rapid Sequencing 10:00-Argument for Risk-Based Sequencing 14:25-Pillars of GDMT in HFpEF

In this on-site episode of Don't Miss a Beat from the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, hosts Muthiah Vaduganathan, MD, MPH, and Steve Greene, MD, break down a pair of trials from the meeting: STRIDE and SOUL. STRIDE Trial The STRIDE trial, funded by Novo Nordisk, was a double-blind, randomized, placebo-controlled study initiated in 2020 to evaluate the effects of semaglutide 1.0 mg (Ozempic) on walking distance in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial enrolled 792 patients, who were randomized 1:1 to receive semaglutide or placebo for 52 weeks. Participants assigned to semaglutide received an escalating dose regimen (0.25 mg to 1.0 mg). The primary endpoint, the ratio from baseline in maximum walking distance at 52 weeks, favored semaglutide (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). Secondary outcomes further supported semaglutide's benefit. At week 57, the improvement in walking distance was greater with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011). Pain-free walking distance also improved more with semaglutide than with placebo (ETR, 1.11; P = .0046). SOUL Trial The SOUL trial was a double-blind, placebo-controlled, event-driven study designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). The trial enrolled 9650 patients aged ≥50 years and was conducted across 450 centers in 44 countries. Participants were randomized 1:1 to receive semaglutide or placebo, with a mean follow-up of 47.5 months. Primary outcome events occurred in 12.0% of participants receiving semaglutide (3.1 events per 100 person-years) compared with 13.8% in the placebo group (3.7 events per 100 person-years), resulting in a hazard ratio (HR) of 0.86 (95% CI, 0.77–0.96; P = .006). The primary driver of benefit was a 26% reduction in nonfatal myocardial infarction, with additional reductions in nonfatal stroke (12%) and cardiovascular death (7%). No significant improvements in kidney function were observed. Serious adverse events occurred slightly less frequently in the semaglutide group compared with placebo (47.9% vs 50.3%; P = .02). However, gastrointestinal adverse events, including nausea, diarrhea, constipation, and flatulence, were more common in the semaglutide group (5.0% vs 4.4%). Benefits were consistent across subgroups, including participants receiving sodium-glucose cotransporter-2 inhibitors. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00 - Intro 00:50 - STRIDE Background 02:50 - STRIDE Results 08:19 - SOUL Background 10:40 - SOUL Results

This episode covers: Cardiology This Week: A concise summary of recent studies Non-bacterial thrombotic endocarditis Managing cardiovascular risk in transgender people Milestones: RAVEL Host: Perry Elliott Guests: Kyle Klarich, Christian Delles Want to watch that episode? Go to: https://esc365.escardio.org/event/1800 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.  This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Christian Delles, Kyle Klarich and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Christian Delles Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1800?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Christian Delles and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial fibrillation in athletes 'Work and life' of a medical journalist Mythbusters: Female doctors with better outcomes Host: Perry Elliott Guests: Carlos Aguiar, Isabelle van Gelder, Shelley Wood Want to watch that episode? Go to: https://esc365.escardio.org/event/1799   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests  Stephan Achenbach, Nicolle Kraenkel, Isabelle van Gelder and Shelley Wood have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Isabelle van Gelder Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1799?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Isabelle van Gelder have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

In this episode of Moving Forward, Giving Back, four of our incredible donors and life sciences leaders sit down for a roundtable discussion about their involvement in our program Life Science Shares. This campaign is a way for companies or individual leaders to contribute to Life Science Cares if and when they reach financial milestones or other positive events by pledging a percentage of a future transaction. Joining the discussion are host Jeff Marrazzo, the co-founder and former CEO of Spark Therapeutics, and guests Sarah Boyce, CEO and President of Avidity Bio, Robert Blum, President and CEO of Cytokinetics and Ron Cooper, Chairman of C4 Therapeutics and former CEO of Albireo Pharma. During this dynamic conversation Jeff, Sarah, Robert and Ron explain their reasons for getting involved with the Life Science Shares initiative and the benefits the decision has had for them personally and for their companies. Learn more about LSC and Life Science Shares at lifesciencecares.org.

Host: Perry Elliott Guest: Hector Bueno Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1796?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Hypertensive disorders during pregnancy Depression and heart disease Mythbusters: "The French Paradox" Host: Perry Elliott Guests: Carlos Aguiar, Martha Gulati, Hector Bueno Want to watch that episode? Go to: https://esc365.escardio.org/event/1796 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Martha Gulati, Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode, Gwen Petersen discusses her long journey to receiving an ALS diagnosis at age 32, her contributions to a Cytokinetics book project, and the importance of clinical trial participation. We are also joined by Merit Cudkowicz, MD, MSc, Head of the Department of Neurology, Chief of Neurology, and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in Boston, MA who discusses the PLATFORM-ALS trial and the drugs currently in the clinical research and development pipeline.

This episode is a discussion of the paper entitled, "Catheter Ablation versus Advanced Therapy for Patients with Severe Heart Failure and Ventricular Electrical Storm." https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.hrthm.2024.09.045 Host Disclosure(s): W.Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): R. Kerley: Nothing to disclose. A. Desai: Research: Novartis, Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Honoraria/Speaking/Consulting: Novartis, Abbott, AstraZeneca, Regerneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceutricals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlacoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Membership on Advisory Committees: BioFourmis

Host: Perry Elliott Guest: Christiaan Vrints Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1793?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Christiaan Vrints has declared to have no potential conflicts of interest to report. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Optimal management of angina Artificial sweeteners and cardiovascular risk Statistics Made Easy: Network meta-analyses Host: Perry Elliott Guests: Carlos Aguiar, Christiaan Vrints, Marco Witkowski Want to watch that episode? Go to: https://esc365.escardio.org/event/1793 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Antonio Greco, Nicolle Kraenkel, Christiaan Vrints and Marco Witkowski have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Which MRA to use in which heart failure patient Managing electrical storm Mythbusters: garlic protects from the heart Host: Perry Elliott Guests: Carlos Aguiar, Sana Al-Khatib, Rudolf de Boer Want to watch that episode? Go to: https://esc365.escardio.org/event/1792 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Sana Al-Khatib and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: direct research funding from European Research Council (ERC), Netherlands Heart Foundation, Fondation leDucq, Netherlands Organization for Scientific Research. Research funding to department or institution: AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, NovoNordisk. Direct fees from Abbott, AstraZeneca, Cardior Pharmaceuticals GmbH, NovoNordisk, Roche Diagnostics. Fees to department or institution: NovoNordisk. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology this Week: A concise summary of recent studies Strategic decisions in atrial fibrillation Critical evaluation of clinical trials Snapshots Host: Perry Elliott Guests: Stephan Achenbach, Carlos Aguiar, Jane Armitage, Isabel Deisenhofer Want to watch that episode? Go to: https://esc365.escardio.org/event/1720 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Jane Armitage and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Drug treatment of hypertrophic cardiomyopathy Humour in medicine Statistics Made Easy: Regression analysis Host: Susanna Price Guests: Carlos Aguiar, Milind Desai, Rohin Francis Want to watch that episode? Go to: https://esc365.escardio.org/event/1156   Disclaimer: ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb. The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Rohin Francis, Antonio Greco, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Milind Desai has declared to have potential conflicts of interest to report: consultant and research agreements with Bristol Myers Squibb, Tenaya, Edgewise, Cytokinetics and VIZ AI. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology this Week: A concise summary of recent studies   Lifetime management of aortic valve stenosis   Spirituality and cardiovascular health  Statistics Made Easy: Statistical Analyses using Chat GPT  Host: Perry Elliott Guests: Carlos Aguiar, Kavitha Chinnaiyan, Francesco Maisano Want to watch that episode? Go to: https://esc365.escardio.org/event/1155   Disclaimer ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb. The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Kavitha Chinnaiyan and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Giuseppe Biondi-Zoccai has declared to have potential conflicts of interest to report : Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Francesco Maisano has declared to have potential conflicts of interest to report : Grant Institute, Edwards, Abbott, NVT, Medtronic, Jenavalve and Boston Scientifics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.      

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.   This episode covers: Cardiology This Week: A concise summary of recent studies State-of-affairs in hypertension treatment Anticoagulation in pregnancy Statistics Made Easy : Accuracy and AUC    Host: Perry Elliott Guests: Carlos Aguiar, Gianfranco Parati, Julie De Backer Want to watch that episode? Go to: https://esc365.escardio.org/event/1152   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Julie De Backer and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Viatris, Merck, Recor, Somnomedics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company's aficamten, its next-in-class cardiac myosin inhibitor, prior to results from a phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. 00:54-02:32: About Cytokinetics02:32-04:11: What are the current treatments for cardiovascular conditions?04:11-05:44: About cardiovascular disease05:44-08:59: What is aficamten?08:59-09:12: How is it administered?09:12-10:04: Where is aficamten on the path to commercialization?10:04-12:06: What does this mean for patients?12:06-12:42: What will you be presenting in Portugal?12:42-16:06: Could aficamten have other applications?16:06-16:50: What is CK-136?16:50-18:02: What is omecamtiv mecarbil?18:02-20:26: Cytokinetics' business modelInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Akshay Suvas Desai, MD, MPH of Brigham and Women's Hospital, and Sunil Kapur, MD of Brigham and Women`s Hospital to discuss how the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization therapy (CRT) than among those who received implantable cardioverter–defibrillators (ICDs). However, the effect of CRT on long-term survival is not known. We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more (or a paced QRS duration of 200 msec or more) to receive either an ICD alone or a CRT defibrillator (CRT-D). We assessed long-term outcomes among patients at the eight highest-enrolling participating sites. The primary outcome was death from any cause; the secondary outcome was a composite of death from any cause, heart transplantation, or implantation of a ventricular assist device.  https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2304542 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research: Medtronic Contributor Disclosure(s): A. Suvas Desai: Honoraria/Speaking/Consulting: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Research: Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis  S. Kapur: Honoraria/Speaking/Consulting: Medtronic, Novartis, Abbott, Biotronik This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode53

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease and sexual activity Rheumatic Heart Disease Snapshots Host: Perry Elliott Guests: Stephan Achenbach, Carlos Aguiar, Pernille Palm, Liesl Zuhlke Want to watch that episode? Go to: https://esc365.escardio.org/event/1145   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Pernille Palm and Liesl Zuhlke have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Extreme temperatures and the heart Paravalvular leak closure Tribute to Alain Cribier Host: Perry Elliott Guests: Carlos Aguiar, Juhani Junttila, Wojciech Wojakowski Want to watch that episode? Go to: https://esc365.escardio.org/event/1146 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests Stephan Achenbach, Juhani Junttila, Nicolle Kraenkel and Wojciech Wojakowski have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Fluid restriction, bed rest, leg compression in acute heart failure Device-detected atrial fibrillation Snapshots  Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Biykem Bozkurt and Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1142 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Biykem Bozkurt has declared to have potential conflicts of interest to report: consulting for Abbott, Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Paulus Kirchhof has declared to have potential conflicts of interest to report: fees from AstraZeneca, Roche Diagnostics, Johnson&Johnson, Philips, Medtronic, Boehringer-Ingelheim, Daiichi Sankyo. Research fundings from Sanofi Adventis, Abbott, German Ministry of Education and Research (BMBF), Daiichi Sankyo, British Heart Foundation, Leducq Foundation, European Union horizon2020, UK Medical Research Council and NIHR (UK National Institute of Health Research). Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

On this week's Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Brad Loncar, Dawn Bell and Sam Fazeli discuss the latest in biotech news, including their takeaways from last week's JPM 2024 conference and Brad's BiotechTV interviews with several attendees. The hosts also discuss the many deals from the week including Merck's acquisition of Harpoon Therapeutics ($680M), Johnson & Johnson's acquisition of Ambrx ($2B), GSK acquires Aiolos Bio ($1.4B), Boston Scientific acquires Axonics ($3.7B) and several Novartis deals including their dropped pursuit of Cytokinetics, acquisition of Calypso ($250M), their licensed drugs from a China biotech ($185M) and their deal with Eli Lilly and Isomorphic Labs ($3B). Other topics include two preclinical companies, Metagenomi and ArriVent file for IPO, Vertex pauses its diabetes cell therapy trial and Astellas gets a CRL. *This episode aired on January 12, 2024

Episode 5 (January 19, 2024); RNAs to address Alzheimer's disease; monkey cloned via somatic cell nuclear transfer; Cytokinetics stock roller coaster; an interview with founder and CEO of 1910 Genetics, Jen Nwankwo, PhD.Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:· Alzheimer's Disease Linked to Toxic Short RNAsGEN, January 18, 2024.· Rhesus Monkey Cloned via Somatic Cell Nuclear TransferGEN, January 16, 2024.· StockWatch: M&A Talk Fuels Cytokinetics Stock Roller CoasterBy Alex Philippidis, GEN Edge, January 16th, 2024. Hosted on Acast. See acast.com/privacy for more information.

What's driving BYD's success to overtake Tesla as the world's most popular EV maker? What are some reasons stock investors will see a bullish 2024 for the S&P 500? And how have Chinese gaming stocks reacted to news of China regulator's reassurance on new online gaming rules? Michelle Martin unpacks it all with Ryan HuangSee omnystudio.com/listener for privacy information.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. Enjoy this special episode with Stephan Achenbach, Carlos Aguiar, Emma Svennberg, David Capodanno and Nicolle Kraenkel who share the most important news in their area of interest and their favourite ESC TV Today episodes! Host: Perry Elliott Guests: Stephan Achenbach, Carlos Aguiar, David Capodanno, Nicolle Kraenkel and Emma Svennberg. Want to watch that episode? Go to: https://esc365.escardio.org/event/1523   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.    Declarations of interests Stephan Achenbach and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

In this podcast Scrip looks at the some upcoming clinical catalysts for biopharma, judged by the size of the sales forecasts at stake. Companies including Sanofi, Cytokinetics, Corcept and Inventiva stand to gain – or lose.

Hypertrophic cardiomyopathy is a rare, genetic heart condition that has a disproportionate impact on people in the Black community because of socio-economic and access issues. Cytonkinetic's experimental therapy aficamten is in late-stage development to treat the condition, but it also reflects a long-term focus of the company to address health inequities. We spoke to Robert Blum, CEO of Cytokinetics, about hypertrophic cardiomyopathy, how the company has worked to build relationships in the black community to expand participation in clinical trials, and how it is thinking ahead to issues of access and affordability as it advances the drug towards the market.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies All you need to know about Lp(a) Chronic total coronary occlusions Statistics Made Easy: The p-value Host: Perry Elliott Guests: Carlos Aguiar, Carlo di Mario, Lale Tokgozoglu Want to watch that episode? Go to: https://esc365.escardio.org/event/1141   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Carlo di Mario and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. Lale Tokgozoglu has declared to have potential conflicts of interest to report: honoraria/consultancy from: Abbott, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Pfizer, Ultragenyx.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies LAA occlusion Chronic thromboembolic pulmonary hypertension Mythbusters: Do cholesterol lowering drugs provoke dementia? Host: Perry Elliott Guests: Carlos Aguiar, Stephan Rosenkranz, Jacqueline Saw Want to watch that episode? Go to: https://esc365.escardio.org/event/1140   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.    Declarations of interests Stephan Achenbach and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.  Stephan Rosenkranz has declared to have potential conflicts of interest to report: speaker fees and consultation for Bayer, MSD, Boehringer-Ingelheim and Inari. Jacqueline Saw has declared to have potential conflicts of interest to report: proctor and consultancy fees from Abbott and Boston Scientific. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for Cardiac Resynchronisation Therapy The polypill for cardiovascular disease prevention Snapshots Host: Perry Elliott Guests: Carlos Aguiar, Cecilia Linde, Valentin Fuster, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/1139 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Valentin Fuster and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Cecilia Linde has declared to have potential conflicts of interest to report: research grants to institutions; Swedish Heart Lung Foundation, Swedish Academy of Science, Stockholm County Council, Roche Diagnostics. Speaker honoria: AstraZeneca, Medtronic, Impulse Dynamics, Vifor, Novartis, Boehringer Ingelheim, MSD, Bayer Advisory Board, AstraZeneca (continuity study), Medtronic (Women and CRT), Medtronic Implementation of CRT and ICD. DSMB: UCS Uppsala ABC Study. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Peripartum cardiomyopathy Arrhythmogenic mitral valve prolapse Statistics Made Easy: The ‘Win Ratio' Host: Perry Elliott Guests: Carlos Aguiar, Johann Bauersachs and Kristina Haugaa Want to watch that episode? Go to: https://esc365.escardio.org/event/1138 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Johann Bauersachs has declared to have potential conflicts of interest to report: direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. by Roche Diagnostics (Acute Heart Failure), Pfizer (Atrial Fibrillation), Bristol Myers Squibb (Atrial Fibrillation), Bayer (Chronic Heart Failure), Boehringer-Ingelheim (Chronic Heart Failure), Novartis (Chronic Heart Failure), CVRx (Chronic Heart Failure), AstraZeneca (Chronic Heart Failure), Cardior (Chronic Heart Failure), Norgine (Chronic Heart Failure). Research funding from healthcare industry under your direct/personal responsibility (to department or institution): Roche Diagnostics (Atrial fibrillation, co-investigator), Norgine (heart failure / iron deficiency, principal investigator), Zoll Medical (heart failure, co-investigator), CVRx (heart failure, investigator). Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/using-glp-1-ras-to-reduce-cv-risk-in-t2d-9134SummaryType 2 diabetes (T2D) doubles a patient's risk for atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of morbidity and mortality in patients with T2D. The 2023 ADA guidelines now recommend consideration of GLP-1 RAs in patients with T2D and ASCVD or indicators of ASCVD risk, independently of A1C and metformin use. In this episode, Dr. Pam Taub reviews recent updates in the cardiovascular benefits and appropriate use of GLP-1 receptor agonists for managing patients with T2D.Learning Objectives Incorporate early use of GLP-1 RA therapy in appropriate patients with T2D using a holistic approach, considering administration route and optimal dosingOvercome barriers to GLP-1 RA uptake and medication adherence in T2D through patient counseling to manage adverse effectsThis activity is accredited for CME/CE CreditAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Association of Black Cardiologists, Inc. (ABC) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, contact NACE at info@naceonline.com.Summary of Individual DisclosuresDr. Taub financial relationships:Consultant: Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Esperion, Merck, Sanofi, Medtronic Contracted Research: Amgen, Novartis All her disclosures are related to cardiologyDr. Morris financial relationships: Consultant and advisor: Acorai, Regeneron, MerckSpeaker: Abbott, BI Lilly, Cytokinetics, Edwards Lifesciences, Ionis Contracted Research: Boston Scientific, Cytokinetics, Ionis, Merck, Myokardia, Novartis Stocks: Gilead Sciences All her disclosures are related to heart failure.All of the relevant financial relationships listed for these individuals have been mitigated.Association of Black Cardiologists Planning CommitteeTierra Dillenburg has no relevant conflicts of interest with any ACCME-defined commercial interest.Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This educational activity is supported by an independent educational grant from Novo Nordisk Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by Kolade Muchaili Agboola, MD, and Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital to discuss the results and implications of the CASTLE-HTx trial.   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): K. Agboola: No relevant financial relationships with ineligible companies to disclose.  A. Desai: Honoraria/Speaking/Consulting Fee: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal; Research (Contracted Grants for PIs Named Investigators Only): Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis

Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, ​​a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases. Robert and Fady discuss how they have developed a company culture that embraces some of the learnings that come along with failure and the advice they would provide other leaders. They talk about how the current capital market environment shapes the way the company is operating. They also discuss the cardiovascular market and overall landscape, where Cytokinetics is from a development perspective, and some upcoming milestones. Finally, they each share a piece of advice they wish they could provide to their younger selves knowing what they now know. Biography: Robert Blum has served as President and Chief Executive Officer of Cytokinetics and a member of our Board of Directors since 2007. Previously, he served as Cytokinetics' President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert previously served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Fady Malik has led Research and Development since 2014 and been with Cytokinetics since its inception in 1998 when he joined its founders to participate in the launch of the company. Early on, Fady recognized the potential therapeutic utility of modulating the sarcomere of cardiac and skeletal muscle and led discovery and development efforts giving rise to Cytokinetics' current portfolio of early- to late-stage development programs targeting muscle contractility for the treatment of cardiovascular and neuromuscular diseases. Fady is an internationally recognized cardiovascular physician-scientist, an inventor on more than 20 issued patents, and has authored or co-authored over 60 publications appearing in prominent journals such as Science, Nature Medicine, the Lancet, and the New England Journal of Medicine. He currently holds an appointment in the Cardiology Division of the University of California, San Francisco, as a Clinical Professor of Medicine and until 2019 was an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers. Fady serves on the Board of Directors for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Fady received a B.S. in bioengineering from the University of California at Berkeley, and a M.D./Ph.D. from the University of California at San Francisco where he also completed an internal medicine residency and fellowship in cardiology.

Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. In these bite-size podcasts, we'll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space ­– all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI's Director of Community Outreach and Engagement. Today, Nadia joins us to talk us through Cytokinetics' phase 3 trial for reldesemtiv.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.

We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Connor Hale and Andrea Park as they discuss medtech's highest paid CEOs. Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting, and an update on the Horizon Therapudics bidding war.  To learn more about topics in this episode: Fierce JPM Week  The top 10 highest-paid medtech CEOs Fierce Biotech's ASH 2022 Coverage Fierce Pharma's ASH 2022 Coverage Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati  FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use  Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war  Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?  AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Pink Sheet reporters and editors discuss a projected decline in accelerated approvals by the US FDA, a new CMS proposed rule requiring generic drug cost sharing tiers, and the negative advisory committee recommendation for Cytokinetics' proposed heart failure treatment.